A recent Clatterbridge Cancer Centre article discussed a pioneering clinical trial for a cancer vaccine. It was administered to a UK man at The Clatterbridge Cancer Centre in hopes of stopping the recurrence of his head and neck cancer. The vaccine consisted of a therapy custom-tailored to the patient’s DNA and designed to enhance his own immune system to keep cancer away permanently. The patient’s head and neck cancer first arrived in 2011, and returned four times, requiring taxing treatment, facial surgery, reconstruction and radiotherapy.
First Person in UK Receives Cancer ‘Vaccine’
A new clinical trial will determine if a year of immunotherapy injections will keep a four-time cancer patient free of recurrence.
Feb 24, 2022
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
